Vascular Endothelial Growth Factor Inhibitor Market Analysis

Some of the restraining factors for VEGF inhibitor to be a silver bullet in the treatment of cancer is that angiogenesis is not the only factor causing a tumor. While the lesser known restraints are the side effects caused by VEGF inhibitors are bleeding and increased blood pressure

Vascular Endothelial Growth Factor Inhibitor Market: Segmentation

The Vascular Endothelial Growth Factor market is segmented according to the mode of action of the drug, route of administration, end users, and geography. The segmentation by mode of action of the drug is tyrosine kinase inhibitor: inhibits the adenosine triphosphate binding site, monoclonal antibody: they bind to VEGF-A preventing it from binding to receptors and activating the signaling cascades that lead to angiogenesis and vascular endothelial growth factor receptor hybrids: act as a decoy receptor and prevents binding of the ligand to its natural receptors. By route of administration, it is segmented as oral and intravenous. By end user, the segmentation is classified as hospitals, ambulatory surgical centers, and cancer research institutes. Segmentation by Geography is North America, West Europe, APEJ, Japan, Eastern Europe, Latin America and the Middle East and Africa.

Vascular Endothelial Growth Factor Inhibitor Market: Overview

Vascular Endothelial Growth Factor Inhibitors are also termed as Angiogenesis Inhibitor which inhibits the growth of the new blood vessels. Angiogenesis Inhibitors are effective in the treatment of cancer macular degeneration in the eye and diseases that involve proliferation of blood vessels. VEGF or angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Endogenous inhibitors are present in the body involved in regulating the process of blood vessel formation. Endogenous inhibitors are derived from the cellular matrix and basement protein. Among the factors responsible for angiogenesis, VEGF is the most potent and has high expression in ovarian, endometrial and cervical cancer. Inhibition of angiogenesis by VEGF requires anti – VEGF / anti – angiogenesis factors which reduce the production of pro – angiogenic factor thereby preventing them from binding to their receptors. The commonly used therapy for VEGF pathway inhibition is a monoclonal antibody against VEGF or VEGFR, soluble VEGFR hybrids, and tyrosine kinase inhibitors. Among this, the most widely used treatment is with monoclonal antibody Bevacizumab.

Vascular Endothelial Growth Factor Inhibitor Market: Regional Overview

The monoclonal antibody segment is growing faster in North America and Europe vascular endothelial growth factor inhibitor marketvascular endothelial growth factor inhibitor market. North America region accounts for the largest market share for tyrosine kinase inhibitor followed by Asia-Pacific and Europe. China will drive the Asia Pacific market by providing growth opportunities from upcoming companies. In the Asia-Pacific market, the countries like China, India and South Asian countries will dominate the market. According to WHO the emerging market for cancer is Africa, Asia, and the US.

Vascular Endothelial Growth Factor Inhibitor Market: Key Players

Some of the  players in the market of Vascular Endothelial Growth Factor Inhibitor are Pfizer Inc., Novartis Pharmaceutical Corporation, AstraZeneca, Bayer Healthcare, Merck & Co. Inc., Genetech Inc., Eli Lilly, Sanofi Aventis, GlaxoSmithKline, Bristol-Myer Squibb and Boehringer Ingelheim

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.